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Abstract
Deep vein thrombosis and pulmonary embolism, collectively termed venous thromboembolism
(VTE), affect over 1 million Americans each year. VTE is triggered by inflammation and blood
stasis leading to the formation of thrombi rich in fibrin and red blood cells (RBCs). However, little
is known about mechanisms regulating fibrin and RBC incorporation into venous thrombi, or how
these components mediate thrombus size or resolution. Both elevated circulating fibrinogen
(hyperfibrinogenemia) and abnormal fibrin(ogen) structure and function, including increased
fibrin network density and resistance to fibrinolysis, have been observed in plasmas from patients
with VTE. Abnormalities in RBC number and/or function have also been associated with VTE
risk. RBC contributions to VTE are thought to stem from their effects on blood viscosity and
margination of platelets to the vessel wall. More recent studies suggest RBCs also express
phosphatidylserine, support thrombin generation, and decrease fibrinolysis. RBC interactions with
fibrin(ogen) and cells, including platelets and endothelial cells, may also promote thrombus
formation. The contributions of fibrin(ogen) and RBCs to the pathophysiology of VTE warrants
further investigation.
Venous thrombosis/thromboembolism (deep vein thrombosis and/or pulmonary embolism;
VTE), affects over 1 million Americans each year [1]. VTE is triggered by intravascular
activation of coagulation and thrombin-mediated intraluminal fibrin deposition [2–4]. Red
blood cells (RBCs) are thought to be incorporated into venous thrombi via passive trapping
in the growing fibrin network, culminating in the production of a RBC- and fibrin-rich
venous thrombus. However, little is known about mechanisms regulating fibrin deposition
and RBC incorporation into venous thrombi, or how fibrin(ogen) and RBCs contribute to
venous thrombus size or resolution. This review will discuss how fibrinogen, RBCs, and
interactions between the two may contribute to VTE.
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As opposed to arterial thrombosis, which arises following atherosclerotic plaque rupture and
exposure of subendothelial cells to blood in high shear (500–1500 s−1), VTE is often
associated with plasma hypercoagulability and thought to be triggered by expression of cell
adhesion molecules and procoagulant activity on intact, but dysfunctional endothelium in
low shear (10–100 s−1 “stasis”). Consequently, whereas arterial thrombi (so called “white
clots”) are platelet-rich, venous thrombi (“red clots”) are high in RBC and fibrin content
(Figure).
VTE is thought to initiate in the hypoxic environment of venous valve pockets [2], where
intravascular activation of coagulation triggers thrombin-mediated fibrin deposition.
Adhesion of neutrophils and monocytes to activated endothelium is a necessary initial step
for venous thrombus formation [3, 4]. Subsequently, myeloid cell expression of TF and
neutrophil extracellular traps promote both extrinsic and intrinsic coagulation [3, 4].
Abnormal expression of both cellular and plasma procoagulant activity have been implicated
as risk factors for development of VTE. Additional common risk factors for VTE include
smoking, trauma, prolonged immobility, infection, and cancer. Chronic venous
insufficiency, post-thrombotic syndrome, and pulmonary embolism are common sequelae.
Fibrinogen
Fibrinogen is a 340 kD plasma glycoprotein that circulates at 2–5 mg/mL. Fibrinogen is
comprised of 2 pairs each of Aα, Bβ, and γ chains arranged as a rod-like protein. When
coagulation is activated, thrombin cleaves fibrinopeptides from the N-termini of the Aα and
Bβ chains permitting polymerization of fibrin monomers into an insoluble fibrin network
[5]. The fibrin network is stabilized by the transglutaminase enzyme factor XIIIa (FXIIIa),
which cross-links γ-γ and γ-α chains within the network, as well as antifibrinolytic proteins
(e.g., α2-antiplasmin) to the network [6]. The fibrin network serves as a scaffold for the
binding of endothelial cells, leukocytes, platelets, and plasma proteins to the clot.
Abnormalities in fibrin(ogen) level and/or function are well-established risk factors for
VTE. An elevated plasma fibrin(ogen) level (hyperfibrinogenemia, >4 mg/mL) significantly
increases the risk of VTE; this risk is concentration-dependent and present across genders
[7]. Using an intravenous infusion strategy to increase levels of circulating fibrinogen in
mice, we observed that hyperfibrinogenemic mice exhibited a shorter time to vessel
occlusion, increased thrombus fibrin content, and increased resistance of thrombi to
thrombolysis compared to controls [8]. These findings suggest hyperfibrinogenemia is not
merely a biomarker of thrombotic risk, but is causative in the etiology of venous thrombosis.
Several studies have correlated increased risk of VTE with increased fibrin network density
and increased resistance of plasma clots to fibrinolysis [9, 10]. These effects are likely
mediated through multiple mechanisms. First, fibrin network structure reflects the
fibrinogen concentration, and the presence of elevated fibrinogen increases fibrin network
density, clot stiffness, and the resistance of clots to fibrinolysis [8]. Second, fibrin network
structure is highly sensitive to the thrombin concentration present during fibrin
polymerization [11]. Hypercoagulable states, such as hyperprothrombinemia, that lead to
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rapid production of high levels of thrombin produce dense fibrin networks composed of
abnormally thin fibers [12, 13]. In addition to the effects of plasma composition on fibrin
quality, fibrin(ogen) bares binding sites for cellular integrins, including αIIbβ3, αMβ2, and
αVβ3, and interactions between the fibrin network and cells increase fibrin network density
and the resistance of clots to fibrinolysis [14]. In situ thrombin generation on the surface of
vascular cells also increases fibrin network density, independent of integrin-fibrin(ogen)
binding [15, 16]. Fibrin(ogen) engagement of leukocyte integrins also upregulates NF-κB
signaling [17] and augments TF expression [18], providing positive feedback for the
thrombin-mediated regulation of fibrin network structure.
Defects in fibrinogen function that result from congenital mutations (dysfibrinogenemia) are
also associated with VTE [19]. The prothrombotic nature of dysfibrinogenemias may relate
to the reduced ability of fibrin(ogen) to bind and sequester thrombin that leads to excessive
thrombin in circulation, defective binding of tissue plasminogen activator or plasminogen to
the fibrin network, and/or abnormal fibrin network structure and resistance to lysis. In one
notable example, a high incidence of fibrinogen mutations has been observed in patients
with chronic thromboembolic pulmonary hypertension (CTEPH), suggesting that abnormal
fibrin structure and/or stability contribute to persistent pulmonary emboli and consequently,
the development of CTEPH [20]. Together these findings place fibrin formation and quality
at the nexus of procoagulant activity and thrombus formation.
RBCs
RBCs are flexible, biconcave, anucleate cells derived from bone marrow. RBCs are the most
abundant cell type in blood, and circulate at ~4.2-6.1x109/mL in humans; numbers are
slightly higher in men than women. Primary RBC function is oxygen transport via its
hemoglobin-rich cytoplasm. RBCs are readily identifiable by most macroscopic and
microscopic techniques, but are often discarded during blood processing for hematological
tests. However, this centrifugal waste may be more important than realized as recent studies
suggest RBCs are not just passive bystanders, but play an active role in coagulation.
A growing body of evidence suggests that abnormal RBC quantity and quality contribute to
clot formation in vivo. Bleeding times shorten as hematocrit rises in anemic, normal, and
polycythemic individuals [21], and elevated RBC levels are associated with increased risk of
venous thrombosis in patients with polycythemia vera or patients on erythropoietin [22, 23].
Patients with sickle cell disease (SCD) have abnormal hemoglobin polymerization resulting
in dysfunctional RBCs with a characteristic “sickled” appearance; notably, SCD patients
have an increased incidence of large-vessel thrombosis, including pulmonary embolism
[24]. However, an etiologic role for RBCs in VTE remains unclear.
RBCs may contribute to thrombosis in several ways. First, RBCs increase blood viscosity
and marginate platelets toward the endothelium, placing them in close proximity to sites of
vascular trauma. Second, a subfraction of RBCs express phosphatidylserine on their surface
and in vitro studies show that RBCs can support thrombin generation, suggesting RBCs may
promote fibrin deposition during venous thrombosis [25, 26]. Interestingly, RBC
phosphatidylserine expression correlates with endogenous markers of activation of
Aleman et al. Page 3






















coagulation in patients with SCD [27]. Third, once in the clot, RBCs appear to exert direct,
complex effects on clot structure and stability. For example, RBCs have been shown to
increase the size of pores in the fibrin network [28], but decrease fibrin network
permeability [29]. Finally, the presence of RBCs in clots suppresses plasmin generation and
reduces clot dissolution [30]. These observations suggest that decreasing thrombus RBC
content would accelerate thrombus resolution.
RBC interactions with vascular cells and fibrin(ogen) during venous
thrombogenesis
Little is known about how RBCs become incorporated into venous thrombi. The existing
paradigm asserts that during venous thrombosis, RBCs become sterically trapped in the
growing fibrin network. However, increasing evidence suggests RBCs are incorporated into
thrombi via specific interactions. RBCs interact with activated endothelial cells and this
interaction was recently demonstrated in a study of arterial thrombosis in which RBCs were
the first cells to adhere to FeCl3-treated intact endothelium, prior to the arrival of platelets
[31]. Integrin-mediated interactions between RBCs and leukocytes and platelets may also
lead to their incorporation into thrombi. RBCs bind to platelet αIIbβ3 and this interaction
depends on the platelet activation state, is metal ion-dependent, and can be inhibited by
arginylglycylaspartic acid-containing peptide, anti-ICAM-4 antibody, or soluble fibrinogen
[32, 33]. RBC ICAM-4 also interacts with leukocyte β1 and β2 integrins [34].
Interestingly, RBCs and fibrin can be found in a “brick-and-mortar” arrangement within
venous thrombi (Figure), raising the possibility that these components directly interact
during venous thrombogenesis. Indeed, RBCs have been shown to interact specifically with
fibrin(ogen), with ~20,000 binding sites/RBC and Kd ~1.3 µM [35]. Two potential receptors
on RBCs have been implicated in fibrin(ogen)-RBC interactions: β3 or a β3-like molecule
[36] and the integrin-associated protein CD47 [37]. Since CD47 was originally identified for
its interaction with αvβ3, αIIbβ3, and α2β1 integrins, it is possible that the fibrinogen-
binding site on RBCs consists of a complex of both of these molecules. Recent intriguing
data from our laboratory suggest that fibrin(ogen)-mediated transport of FXIII(a) to the clot
is necessary for RBC retention in thrombi; compared to wild type mice, mice with reduced
or delayed FXIIIa activation produce smaller venous thrombi with reduced RBC content
[38]. Whether FXIIIa activity is necessary to stabilize the fibrin network or directly cross-
link RBCs into the clot remains to be determined.
Conclusions and Future Directions
Together, these observations imply that fibrin(ogen) and RBCs are not only major
components of venous thrombi and determinants of VTE risk, but also actively contribute to
the pathophysiology of VTE. Clearly, continued research into the prothrombotic nature of
both RBCs and fibrin(ogen) is warranted, with a particular emphasis on the physical and
biochemical interactions between RBCs, fibrin(ogen), and vascular cells. Disrupting the
incorporation of fibrin(ogen) and/or RBCs into venous thrombi has high potential
therapeutic value for reducing VTE and VTE-related sequelae.
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Figure. Human pulmonary embolus micrograph
Pulmonary embolus was collected at autopsy at UNC Hospitals and fixed in glutaraldehyde for transmission electron
microscopy (2000X magnification). Note the “brick-and-mortar” organization of RBCs and fibrin within the thrombus.
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